Beth C. Seidenberg - Feb 9, 2023 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Feb 9, 2023
Transactions value $
$2,900
Form type
4
Date filed
2/13/2023, 03:04 PM
Previous filing
Feb 9, 2023
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Purchase $2.9K +400 +0.02% $7.25 1.65M Feb 9, 2023 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were purchased as follows: 387 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 13 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein.
F2 Consists of 1,599,864 shares of Class A Common Stock held by KPCB XVI and 54,766 shares of Class A Common Stock held by XVI Founders.